Cerebras Earnings Beat But Stock Falls

Cerebras Systems posted first quarter revenue of $193.4 million as a newly public company, beating the analyst consensus by roughly $10 million, yet shares of CBRS fell 15% in early Wednesday trading to approximately $192, the lowest print since the stock began trading last month. The selloff reflects a straightforward concern: gross margin compression.

At a Glance

• Q1 revenue of $193.4 million exceeded the Visible Alpha consensus by about $10 million
• Adjusted net loss of $2.48 million, narrower than analyst forecasts
• Q2 adjusted gross margin guidance of 36% to 38%, down from 47% in Q1
• Shares off roughly 40% from their first-day close, about 4% above the $185 IPO price
• Morgan Stanley raised its price target to $273 from $250, citing strong chip demand

The Numbers Behind the Drop

A beat on the top line and a narrower than expected loss would ordinarily support a stock. The problem is the margin trajectory. Cerebras guided for adjusted gross margins of 36% to 38% in the current quarter, a meaningful step down from the 47% it delivered in Q1. That roughly 9 to 11 percentage point contraction signals cost pressure building faster than revenue can offset it, at least in the near term.

For a semiconductor company at this stage, gross margin is the primary signal investors use to judge pricing power and manufacturing efficiency. A slide from 47% to the midpoint of that guidance range, around 37%, in a single quarter raises questions about whether Q1 was anomalously clean or whether Q2 will be anomalously difficult. The market, for now, is pricing in the more cautious interpretation.

IPO Trajectory and Market Context

Cerebras began trading last month, and the first few weeks were volatile even before Wednesday's print. The 15% single-day drop extends a slide that has now erased nearly 40% of the stock's value relative to where it closed on day one of trading. At roughly $192, shares sit only about 4% above the $185 IPO price, a thin cushion that becomes meaningful if selling pressure continues.

The stock's behavior fits a pattern common among AI infrastructure names that debut during periods of peak enthusiasm and then get repriced as actual reported financials introduce real cost structures into the story. Cerebras is no exception: the initial pop reflected expectations about AI chip demand, and the current correction reflects the reality that margin profiles matter as much as revenue growth.

What the Q1 Results Actually Show

The $10 million revenue beat is genuine and the adjusted loss figure is modest relative to the company's revenue base, which suggests the core business is generating cash at a reasonable clip. The concern is not with Q1 itself but with what the Q2 margin guide implies about the cost structure going forward.

Morgan Stanley's Contrarian Read

Morgan Stanley analysts pushed back on the selloff Wednesday, raising their price target to $273 from $250 while maintaining a bullish stance. Their note to clients argued that nothing in the reported numbers was disappointing and attributed the weak forward guidance partly to conservatism typical of a company navigating its first few quarters under public market scrutiny.

That framing is worth examining quantitatively. If CBRS is at $192 and Morgan Stanley's target is $273, the implied upside is roughly 42%. A target that far above the current price, set by a firm that just raised it, reflects conviction that the margin compression is transitory rather than structural. Whether that view holds depends on how Q2 closes and what the company communicates about the trajectory back toward the 47% Q1 level.

Margin Compression: Structural or Cyclical?

The 47% Q1 gross margin was strong for a company at this revenue scale in the AI chip space. A drop to 36% to 38% in a single quarter is large enough to warrant scrutiny, but not necessarily alarming if it reflects a specific contract mix, product transition, or ramp cost rather than a repricing of the core product. Cerebras has not publicly broken down the drivers of the expected compression in granular terms, which leaves analysts working with limited data.

The key variable is whether gross margin recovers in subsequent quarters. Companies in capital intensive semiconductor production often see lumpy margin profiles early in their public life as they scale capacity. If Cerebras can demonstrate a path back toward the 40s by the second half of the year, the Morgan Stanley bull case gains credibility. If margins remain compressed or decline further, the stock's current premium over its IPO price becomes harder to defend.

Frequently Asked Questions

Why did Cerebras stock fall after beating estimates?

Despite exceeding revenue and loss estimates in Q1, Cerebras guided for adjusted gross margins of 36% to 38% in Q2, down sharply from 47% in Q1. Investors typically sell on forward margin deterioration even when current quarter results are strong, because gross margin signals pricing power and cost efficiency going forward.

How far is CBRS from its IPO price?

At approximately $192 following Wednesday's drop, Cerebras shares trade about 4% above the $185 IPO price. They are down nearly 40% from their first day closing price, reflecting the volatility that has accompanied the stock since it began trading last month.

What is Morgan Stanley's price target for Cerebras?

Morgan Stanley raised its price target to $273 from $250 on Wednesday, implying roughly 42% upside from the post-earnings price near $192. The firm cited strong demand for Cerebras chips and suggested the company may be guiding conservatively as it adjusts to public market reporting cycles.

What drove Cerebras Q1 revenue above expectations?

Cerebras generated $193.4 million in Q1 revenue, approximately $10 million above the Visible Alpha analyst consensus. The company did not break out specific contract or customer details, but the beat alongside a smaller than expected adjusted loss suggests the business scaled efficiently in the quarter.

What Comes Next for Cerebras

The next major data point is Q2 results. If actual gross margins land at or above the guided 36% to 38% range and management offers a credible path back toward Q1 levels, the current selloff may look like an overreaction. If margins miss the low end of guidance or compress further, the stock's thin margin above its IPO price comes under real pressure. Morgan Stanley's revised target of $273 sets a clear benchmark against which the next few quarters will be measured.